Gan & Lee Pharmaceuticals
http://www.ganlee.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Gan & Lee Pharmaceuticals
Biocon Eyes 'Foothold To Stronghold' For (b)Humira In US, Pauses RH-Insulin Program
Biocon sees some wins for biosimilar adalimumab in the US and signals more opportunities amid the slower than anticipated build-out for Humira rivals. Chinese competition looms for glargine, but the Indian company declares it “will be competitive if these folks launch.”
Biocon Eyes 'Foothold To Stronghold' For (b)Humira In US, Pauses RH-Insulin Program
Biocon sees some wins for biosimilar adalimumab in the US and signals more opportunities amid the slower than anticipated build-out for Humira rivals. Chinese competition looms for glargine, but the Indian company declares it “will be competitive if these folks launch.”
Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
Uncertain Times: New Lockdowns, Ukraine Challenge Chinese Pharma
As residents of China's largest city brace for a possible prolonged lockdown, the gathering COVID-19 outbreak is set to cause some pharma disruption in the country, while broader geopolitical factors including Ukraine are hindering the industry's global ambitions.
Company Information
- Industry
- Medical Devices
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Gan & Lee Pharmaceuticals Shandong Co., Ltd
- Gangan Medical Technology Jiangsu Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice